Overview

Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma

Status:
NOT_YET_RECRUITING
Trial end date:
2030-05-01
Target enrollment:
Participant gender:
Summary
Previously untreated patients with follicular lymphoma are treated with the ZGCVP regimen (zanubrutinib, obinutuzumab, cyclophosphamide, vindesine, prednisolone) for 6 cycles.
Phase:
PHASE2
Details
Lead Sponsor:
Zhejiang Cancer Hospital